Barcelona-based Biorce has announced a $52 million Series A funding round to support the global rollout of its artificial intelligence (AI) platform for clinical trial design and execution.

Aika: the AI platform at the heart of Biorce's strategy

At the core of Biorce's offering is Aika, an AI-native platform designed to reduce clinical trial preparation timelines and limit protocol amendments. The goal is to accelerate the development of new therapies, reducing the costs associated with protocol changes, which can amount to considerable figures and delay patient recruitment.

Aika is built on a dataset of approximately one million clinical trials and aims to anticipate risks, reduce errors, and limit the need for protocol changes. The platform supports pharmaceutical companies, biotech firms, and contract research organizations (CROs) in designing more efficient trials, while maintaining high scientific standards and patient safety.

Expansion and future developments

Biorce plans to expand its team and open a development and R&D hub in Austin, Texas, to support activities in the United States. By 2026, the company intends to further develop Aika's protocol intelligence capabilities and introduce additional modules for contract management, negotiation, budget planning, and operational execution.